MPP-Home

en / fr

Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements

Read the joint MPP-ViiV Healthcare press release on the occasion of the five-year anniversary of the signing of their licences on dolutegravir.

2018 Annual Report: Expanding Access to Public Health

We are pleased to present our 2018 Annual Report, which has as its theme, “Expanding Access to Public Health." Discover on how this is fundamental to the mission of the MPP.

The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate

The MPP published in May a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Projections

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

26 million patient-years through MPP’s generic partners from January 2012 to June 2019

23 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

150+

150+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

1.23

1.23 billion dollars saved, from January 2012 to June 2019

Latest News

02 October 2019

The Medicines Patent Pool publishes intellectual property status of 18 drugs added to WHO Essential Medicines List

Geneva, 2 October 2019 — The Medicines Patent Pool today announced the first of a two-step update of its database MedsPaL to include additional patented small molecule medicines following the publication of the World Health Organization (WHO)’s updated Model List of Essential Medicines (EML) in July. Launched in 2016, MedsPaL is a free resource on the intellectual property status of patented medicines included in the WHO EML for low- and middle-income countries (LMICs). Initially covering selected HIV, hepatitis C and tuberculosis medicines in LMICs, MedsPaL expanded to all patented treatments on the EML in 2017. “We are passionate in our belief that public health stakeholders must have simplified access to accurate patent information on essential medicines in order to make informed decisions when the time comes to procure and supply those important drugs to the people who need them,” said Charles Gore, Executive Director of the Medicines Patent Pool. “MedsPaL now provides patent and licensing data cove...

30 July 2019

Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements

Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe Geneva & London, 30 July 2019. This year marks the fifth anniversary of the signing of two licensing agreements between ViiV Healthcare and the Medicines Patent Pool (MPP) that have allowed generic manufacturers to produce and sell single and combination versions of dolutegravir (DTG) for adults and children in countries with the highest burden of HIV.[i][ii] Currently, 18 generic manufacturers (17 sublicensees under the MPP and Aurobindo Pharma via a separate direct voluntary licence agreement with ViiV Healthcare[1]) are authorised to produce and sell low-cost single or fixed-dose combination versions of DTG in all least developed, low-income, lower-middle income, and sub-Saharan African countries as well as some other upper middle-income countries (paediatric licence only), totalling 94 and 121 countries for the adult and paediatric agreements respectively.[iii][iv] These licensing agreements...

22 July 2019

The Medicines Patent Pool stands ready to support scale-up of key HIV medicines recommended by the World Health Organization in its newly updated HIV Treatment Guidelines

As the World Health Organization (WHO) releases its guidelines Update of recommendations on first- and second-line antiretroviral regimens, the Medicines Patent Pool (MPP) confirms that high-quality affordable versions of key HIV treatments can already be rolled out in developing countries through MPP generic manufacturing partners and other stakeholders. The MPP holds licences for dolutegravir (DTG), part of the WHO preferred first- and second-line treatments, which allow generic manufacturers to develop and supply DTG containing regimens to people living with HIV in 94 low- and middle-income countries (adult use) and 121 countries (paediatric use). Seven MPP manufacturing partners have already supplied DTG and DTG-based regimens in 66 countries. The MPP also holds licences for lopinavir/ritonavir (LPV/r), the recommended preferred second-line treatment when DTG-based regimens have failed; tenofovir alafenamide (TAF), part of WHO-recommended regimens as alternative in children and in special circumstan...

Videos

Unable to load video, please allow cookie

Endorsements

“With the help of partners like the MPP, the Global Fund has accelerated access to key new products in the countries it supports, putting 18.9 million people on antiretroviral therapy for HIV in 2018, and providing more than 83% of HIV-positive mothers with...”

Unable to load twitter timeline, please allow cookie